Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Big Data Could Help Trial Recruitment But Would Not Replace RCTs

This article was originally published in The Pink Sheet Daily

Executive Summary

Massive collections of clinical data can now be analyzed in seconds rather than in days, and could help in recruiting patients into clinical studies, but the randomized clinical trial is likely to remain the favored way of finding answers to clinical questions.

You may also be interested in...

“Real-World” Breo Study: A Q&A With GSK’s David Leather

GlaxoSmithKline is evaluating its once-daily ICS/LABA Breo Ellipta in a “real-world” trial called the Salford Lung Study, with as little intervention from the clinical trial team as possible, to see how the product impacts health outcomes versus existing treatments. David Leather, MD, global medical affairs leader for GSK’s respiratory franchise, is heading the trial and talks about the trial design, challenges, and why the company launched the study in the first place.

HIV Market To Meet Patent Cliff In 2026-27 But Novel Products Coming

Market Snapshot: Gilead’s Biktarvy and ViiV’s two-drug regimens are expected to dominate the HIV market over the next few years as market exclusivity losses loom, but drugs with new mechanisms of action, and longer-acting products, might influence market dynamics.   

AACR Round-Up: Zentalis, Pieris, Hookipa And Eli Lilly

Zentalis outlines promising antitumor activity associated with its WEE1 inhibitor, Phase II trials are planned for Pieris Pharmaceuticals’ fusion protein in HER2-positive cancers, while HPV-positive cancers are being targeted by Hookipa’s immunotherapeutics in arenavirus vectors, and Eli Lilly is planning early-stage clinical trials with its next-generation KRAS inhibitor.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts